I
Ingo K. Mellinghoff
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 214
Citations - 26732
Ingo K. Mellinghoff is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Glioma & Medicine. The author has an hindex of 60, co-authored 176 publications receiving 21800 citations. Previous affiliations of Ingo K. Mellinghoff include Howard Hughes Medical Institute & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M. Samstein,Chung-Han Lee,Chung-Han Lee,Alexander N. Shoushtari,Alexander N. Shoushtari,Matthew D. Hellmann,Matthew D. Hellmann,Ronglai Shen,Yelena Y. Janjigian,Yelena Y. Janjigian,David Barron,Ahmet Zehir,Emmet Jordan,Antonio Omuro,Thomas Kaley,Sviatoslav M. Kendall,Robert J. Motzer,Robert J. Motzer,A. Ari Hakimi,Martin H. Voss,Martin H. Voss,Paul Russo,Jonathan E. Rosenberg,Jonathan E. Rosenberg,Gopa Iyer,Gopa Iyer,Bernard H. Bochner,Dean F. Bajorin,Dean F. Bajorin,Hikmat Al-Ahmadie,Jamie E. Chaft,Jamie E. Chaft,Charles M. Rudin,Charles M. Rudin,Gregory J. Riely,Gregory J. Riely,Shrujal S. Baxi,Shrujal S. Baxi,Alan L. Ho,Alan L. Ho,Richard J. Wong,David G. Pfister,David G. Pfister,Jedd D. Wolchok,Jedd D. Wolchok,Christopher A. Barker,Philip H. Gutin,Cameron Brennan,Viviane Tabar,Ingo K. Mellinghoff,Lisa M. DeAngelis,Charlotte E. Ariyan,Nancy Y. Lee,William D. Tap,William D. Tap,Mrinal M. Gounder,Mrinal M. Gounder,Sandra P. D'Angelo,Sandra P. D'Angelo,Leonard B. Saltz,Leonard B. Saltz,Zsofia K. Stadler,Zsofia K. Stadler,Howard I. Scher,Howard I. Scher,José Baselga,José Baselga,Pedram Razavi,Pedram Razavi,Christopher A. Klebanoff,Christopher A. Klebanoff,Rona Yaeger,Rona Yaeger,Neil H. Segal,Neil H. Segal,Geoffrey Y. Ku,Geoffrey Y. Ku,Ronald P. DeMatteo,Marc Ladanyi,Naiyer A. Rizvi,Michael F. Berger,Nadeem Riaz,David B. Solit,Timothy A. Chan,Luc G. T. Morris +84 more
TL;DR: Analysis of advanced cancer patients treated with immune-checkpoint inhibitors shows that tumor mutational burden, as assessed by targeted next-generation sequencing, predicts survival after immunotherapy across multiple cancer types.
Journal ArticleDOI
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu,Patrick S. Ward,Patrick S. Ward,Gurpreet S. Kapoor,Dan Rohle,Dan Rohle,Sevin Turcan,Omar Abdel-Wahab,Christopher R. Edwards,Raya Khanin,Maria E. Figueroa,Ari Melnick,Kathryn E. Wellen,Donald M. O'Rourke,Shelley L. Berger,Timothy A. Chan,Ross L. Levine,Ingo K. Mellinghoff,Ingo K. Mellinghoff,Craig B. Thompson +19 more
TL;DR: It is reported that 2HG-producing IDH mutants can prevent the histone demethylation that is required for lineage-specific progenitor cells to differentiate into terminally differentiated cells, and that inhibition of histone methylation can be sufficient to block the differentiation of non-transformed cells.
Journal ArticleDOI
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan,Daniel Rohle,Daniel Rohle,Anuj Goenka,Logan A. Walsh,Fang Fang,Emrullah Yilmaz,Carl Campos,Armida W. M. Fabius,Chao Lu,Chao Lu,Patrick S. Ward,Patrick S. Ward,Craig B. Thompson,Andrew Kaufman,Olga A. Guryanova,Ross L. Levine,Adriana Heguy,Agnes Viale,Luc G. T. Morris,Jason T. Huse,Ingo K. Mellinghoff,Ingo K. Mellinghoff,Timothy A. Chan,Timothy A. Chan +24 more
TL;DR: It is demonstrated that mutation of a single gene, isocitrate dehydrogenase 1 (IDH1), establishes CIMP by remodelling the methylome, and the epigenomic alterations resulting from mutant IDH1 activate key gene expression programs, characterize G-CIMP-positive proneural glioblastomas but not other gliOBlastomas, and are predictive of improved survival.
Journal ArticleDOI
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Ingo K. Mellinghoff,Maria Y. Wang,Igor Vivanco,Daphne A. Haas-Kogan,Shaojun Zhu,Ederlyn Q. Dia,Kan V. Lu,Koji Yoshimoto,Julie H. Y Huang,Dennis J. Chute,Bridget L. Riggs,Steve Horvath,Linda M. Liau,Webster K. Cavenee,P. Nagesh Rao,Rameen Beroukhim,Rameen Beroukhim,Rameen Beroukhim,Timothy C. Peck,Timothy C. Peck,Timothy C. Peck,Jeffrey C. Lee,Jeffrey C. Lee,Jeffrey C. Lee,William R. Sellers,William R. Sellers,William R. Sellers,David Stokoe,Michael D. Prados,Timothy F. Cloughesy,Charles L. Sawyers,Paul S. Mischel +31 more
TL;DR: Coexpression of EGFRvIII and PTEN by glioblastoma cells is associated with responsiveness to EGFR kinase inhibitors, and effects of the molecular abnormalities in vitro are identified.
Journal ArticleDOI
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
Rameen Beroukhim,Gad Getz,Leia Nghiemphu,Jordi Barretina,Teli Hsueh,David Linhart,Igor Vivanco,Jeffrey C. Lee,Julie H. Huang,Sethu Alexander,Jinyan Du,Tweeny R Kau,Roman K. Thomas,Kinjal Shah,Horacio Soto,Sven Perner,John R. Prensner,Ralph M. Debiasi,Francesca Demichelis,Charlie Hatton,Mark A. Rubin,Levi A. Garraway,Stan F. Nelson,Linda M. Liau,Paul S. Mischel,Timothy F. Cloughesy,Matthew Meyerson,Todd Golub,Eric S. Lander,Ingo K. Mellinghoff,William R. Sellers +30 more
TL;DR: A systematic method, called Genomic Identification of Significant Targets in Cancer (GISTIC), designed for analyzing chromosomal aberrations in cancer, is used to study gliomas and the results support the feasibility and utility of systematic characterization of the cancer genome.